Not Yet Recruiting PHASE1/PHASE2 INTERVENTIONAL 3-arm
NCT07407933
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
A Phase Ib/II, Multicenter, Open-Label Study to Evaluate Safety, Efficacy, and Pharmacokinetics of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
Sponsor: Genentech, Inc.
Interventions
Atezolizumab YL201
Updated 1 time since 2026 Last updated: Feb 6, 2026 Started: Mar 31, 2026 Primary completion: Nov 30, 2028 Completion: Feb 28, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE1/PHASE2 trial investigates Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma and is currently actively recruiting participants. Genentech, Inc. leads this study, which shows 1 recorded version since 2026 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE1/PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Genentech, Inc.
- Hoffmann-La Roche
- MediLink Therapeutics (Suzhou) Co., Ltd.
Data source: MediLink Therapeutics (Suzhou) Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .